GLP facility advantage PrimmBiotech operates a modern GLP-certified animal facility, signaling high-quality preclinical capabilities that can support prospective clients seeking compliant in vivo studies and toxicology data generation.

Integrated services The company offers a fully integrated suite including monoclonal and polyclonal antibodies, peptides, protein analysis, and pharmacological services, enabling end-to-end collaboration with researchers and reducing vendor churn for oncology biomarker programs.

Cancer biomarker focus Active collaborations with leading cancer institutes and utilization of the Yomics Antibody Library for biomarker discovery present a compelling entry point for partnerships in oncology diagnostics, therapeutics, and translational research.

Global footprint With Primm SRL in Milan and PrimmBiotech, Inc. in Cambridge, MA, the company combines European and US access, enabling cross-border projects, regional support, and potential for multinational contract research opportunities.

Market positioning Competitive landscape includes large CROs and biotech suppliers; PrimmBiotech’s specialized antibody library, GLP facility, and established international clientele position it to win share in mid-tier exploratory studies and niche biomarker programs.